Advertisement

A Case-Based Review on the Diagnosis and Treatment Options for Recurrent Wheezing and Asthma in Preschool Children

  • Maleewan KitcharoensakkulEmail author
  • Leonard B. Bacharier
Allergic Asthma (DES Larenas-Linnemann de Martinez, Section Editor)
  • 2 Downloads
Part of the following topical collections:
  1. Topical Collection on Allergic Asthma

Abstract

Purpose of review

To summarize the recent evidence on the various wheezing patterns in early life and provide a case-based review with insights into clinical application of individualized therapy in preschool children with recurrent wheezing.

Recent findings

Preschool wheezing is often characterized predominantly by the risk domain with exacerbations and relatively limited impairment. In children with intermittent disease and a positive Modified Asthma Predictive Index, intermittent therapy with inhaled corticosteroids (ICSs) should be considered as an initial therapy to prevent exacerbations. Early administration of azithromycin at the onset of lower respiratory tract infections (LRTIs) reduces the risks of progression to severe illnesses in children who have a history of recurrent severe LRTIs, and more information is needed regarding the risks of developing drug-resistant organisms. In preschool children with mild persistent asthma, allergic sensitization to aeroallergens and absolute eosinophil count can help identify children most likely to have a good response to daily ICS.

Summary

Recent clinical trials in preschool children with severe episodic wheezing and persistent asthma have made a significant impact on the approach for the care of these children, particularly with evidence directing individualized approaches based on specific clinical features and biomarkers.

Keywords

Recurrent wheezing Preschool Asthma Phenotypes 

Notes

Compliance with ethical standards

Conflict of interest

Leonard Bacharier reports personal fees from Aerocrine, personal fees from GlaxoSmithKline, personal fees from Genentech/Novartis, personal fees from Merck, personal fees from DBV Technologies, personal fees from Teva, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from WebMD/Medscape, personal fees from Sanofi/Regeneron, personal fees from Vectura, and personal fees from Circassia outside the submitted work. Maleewan Kitcharoensakkul declares no conflicts of interest relevant to this manuscript.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children’s Respiratory study: 1980 to present. J Allergy Clin Immunol. 2003;111(4):661–75 quiz 76.CrossRefGoogle Scholar
  2. 2.
    • Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackson DJ, Szefler SJ, Beigelman A, et al. Phenotypes of recurrent wheezing in preschool children: identification by latent class analysis and utility in prediction of future exacerbation. J Allergy Clin Immunol Pract. 2019;7(3):915–24 e7. This article showed sensitization and exposure assessments are useful predictors of future exacerbation in children aged 12 to 71 months.CrossRefGoogle Scholar
  3. 3.
    Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980–2007. Pediatrics. 2009;123(Suppl 3):S131–45.CrossRefGoogle Scholar
  4. 4.
    Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National surveillance of asthma: United States, 2001–2010. Vital Health Stat 3. 2012;35:1–58.Google Scholar
  5. 5.
    Taussig LM, Wright AL, Morgan WJ, Harrison HR, Ray CG. The Tucson Children’s Respiratory study. I. Design and implementation of a prospective study of acute and chronic respiratory illness in children. Am J Epidemiol. 1989;129(6):1219–31.CrossRefGoogle Scholar
  6. 6.
    Halonen M, Stern DA, Lohman C, Wright AL, Brown MA, Martinez FD. Two subphenotypes of childhood asthma that differ in maternal and paternal influences on asthma risk. Am J Respir Crit Care Med. 1999;160(2):564–70.CrossRefGoogle Scholar
  7. 7.
    Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol. 2004;114(6):1282–7.CrossRefGoogle Scholar
  8. 8.
    Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1403–6.CrossRefGoogle Scholar
  9. 9.
    Guilbert TW. Identifying and managing the infant and toddler at risk for asthma. J Allergy Clin Immunol. 2010;126(2):417–22.CrossRefGoogle Scholar
  10. 10.
    Chang TS, Lemanske RF Jr, Guilbert TW, Gern JE, Coen MH, Evans MD, et al. Evaluation of the Modified Asthma Predictive Index in high-risk preschool children. J Allergy Clin Immunol Pract. 2013;1(2):152–6.CrossRefGoogle Scholar
  11. 11.
    Biagini Myers JM, Schauberger E, He H, Martin LJ, Kroner J, Hill GM, et al. A Pediatric Asthma Risk Score to better predict asthma development in young children. J Allergy Clin Immunol. 2018.Google Scholar
  12. 12.
    Bacharier LB. The recurrently wheezing preschool child-benign or asthma in the making? Ann Allergy Asthma Immunol. 2015;115(6):463–70.CrossRefGoogle Scholar
  13. 13.
    Beigelman A, Bacharier LB. Management of preschool recurrent wheezing and asthma: a phenotype-based approach. Curr Opin Allergy Clin Immunol. 2017;17(2):131–8.CrossRefGoogle Scholar
  14. 14.
    Bacharier LB, Guilbert TW. Diagnosis and management of early asthma in preschool-aged children. J Allergy Clin Immunol. 2012;130(2):287–96; quiz 97–8.CrossRefGoogle Scholar
  15. 15.
  16. 16.
    Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97.CrossRefGoogle Scholar
  17. 17.
    Schokker S, Kooi EM, de Vries TW, Brand PL, Mulder PG, Duiverman EJ, et al. Inhaled corticosteroids for recurrent respiratory symptoms in preschool children in general practice: randomized controlled trial. Pulm Pharmacol Ther. 2008;21(1):88–97.CrossRefGoogle Scholar
  18. 18.
    Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, Parasuraman B. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics. 2003;112(3 Pt 1):e212–9.CrossRefGoogle Scholar
  19. 19.
    Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120(5):1043–50.CrossRefGoogle Scholar
  20. 20.
    Brand PL, Luz Garcia-Garcia M, Morison A, Vermeulen JH, Weber HC. Ciclesonide in wheezy preschool children with a positive asthma predictive index or atopy. Respir Med. 2011;105(11):1588–95.CrossRefGoogle Scholar
  21. 21.
    Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. 2009;123(3):e519–25.CrossRefGoogle Scholar
  22. 22.
    Nagao M, Ikeda M, Fukuda N, Habukawa C, Kitamura T, Katsunuma T, et al. Early control treatment with montelukast in preschool children with asthma: a randomized controlled trial. Allergol Int. 2018;67(1):72–8.CrossRefGoogle Scholar
  23. 23.
    Keskin O, Arik Yilmaz E, Motzkus C, Sackesen C, Lilly CM, Kalayci O. The effect of montelukast on early-life wheezing: a randomized, double-blinded placebo-controlled study. Pediatr Allergy Immunol. 2018;29(1):50–7.CrossRefGoogle Scholar
  24. 24.
    Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171(4):315–22.CrossRefGoogle Scholar
  25. 25.
    Wang XP, Yang LD, Zhou JF. Montelukast and budesonide combination for children with chronic cough-variant asthma. Medicine (Baltimore). 2018;97(30):e11557.CrossRefGoogle Scholar
  26. 26.
    Szefler SJ, Carlsson LG, Uryniak T, Baker JW. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J Allergy Clin Immunol Pract. 2013;1(1):58–64.CrossRefGoogle Scholar
  27. 27.
    • Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review. Pediatr Pulmonol. 2018;53(12):1670–7. The article demonstrated daily inhaled corticosteroids is more effective than daily montelukast for improving asthma control and decreasing exacerbations in preschool children.CrossRefGoogle Scholar
  28. 28.
    • Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608-18 e12. The majority of preschool children with mild persistent asthma had differential responses to either daily ICS, daily LTRA or symptom-driven ICS treatment. Aeroallergen sensitization and blood eosinophil counts are useful to identify children who will most likely have a good response to daily ICS.Google Scholar
  29. 29.
    Depner M, Fuchs O, Genuneit J, Karvonen AM, Hyvarinen A, Kaulek V, et al. Clinical and epidemiologic phenotypes of childhood asthma. Am J Respir Crit Care Med. 2014;189(2):129–38.Google Scholar
  30. 30.
    • Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics. 2016;137(6). The article emphasized the efficacy of daily ICS to prevent exacerbations in preschool children with persistent asthma and of intermittent ICS to prevent exacerbations in children with intermittent diseases.Google Scholar
  31. 31.
    Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ, Lemanske RF Jr, et al. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol. 2009;123(5):1077–82 82 e1–5.CrossRefGoogle Scholar
  32. 32.
    Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF Jr, Szefler SJ, et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J Allergy Clin Immunol. 2011;128(5):956–63 e1–7.CrossRefGoogle Scholar
  33. 33.
    Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127–35 e8.CrossRefGoogle Scholar
  34. 34.
    Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med. 2009;360(4):339–53.CrossRefGoogle Scholar
  35. 35.
    Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011;365(21):1990–2001.CrossRefGoogle Scholar
  36. 36.
    Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest. 2007;131(1):180–6.CrossRefGoogle Scholar
  37. 37.
    Krawiec M, Strzelak A, Krenke K, Modelska-Wozniak I, Jaworska J, Kulus M. Fluticasone or montelukast in preschool wheeze: a randomized controlled trial. Clin Pediatr (Phila). 2015;54(3):273–81.CrossRefGoogle Scholar
  38. 38.
    Proesmans M, Sauer K, Govaere E, Raes M, De Bilderling G, De Boeck K. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr. 2009;98(11):1830–4.CrossRefGoogle Scholar
  39. 39.
    Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–60.CrossRefGoogle Scholar
  40. 40.
    Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol. 2011;106(6):518–26.CrossRefGoogle Scholar
  41. 41.
    Wang X, Zhou J, Zhao X, Yi X. Montelukast treatment of acute asthma exacerbations in children aged 2 to 5 years: a randomized, double-blind, placebo-controlled trial. Pediatr Emerg Care. 2018;34(3):160–4.CrossRefGoogle Scholar
  42. 42.
    • Hussein HR, Gupta A, Broughton S, Ruiz G, Brathwaite N, Bossley CJ. A meta-analysis of montelukast for recurrent wheeze in preschool children. Eur J Pediatr. 2017;176(7):963–9. The meta-analysis found montelukast was ineffective in reducing oral corticosteroid uses for preschool wheeze.CrossRefGoogle Scholar
  43. 43.
    Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. J Allergy Clin Immunol. 2014;133(5):1301–7, 7 e1–3.CrossRefGoogle Scholar
  44. 44.
    Lee WM, Lemanske RF Jr, Evans MD, Vang F, Pappas T, Gangnon R, et al. Human rhinovirus species and season of infection determine illness severity. Am J Respir Crit Care Med. 2012;186(9):886–91.CrossRefGoogle Scholar
  45. 45.
    Bashir H, Grindle K, Vrtis R, Vang F, Kang T, Salazar L, et al. Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. J Allergy Clin Immunol. 2018;141(2):822–4 e9.CrossRefGoogle Scholar
  46. 46.
    Slater M, Rivett DW, Williams L, Martin M, Harrison T, Sayers I, et al. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax. 2014;69(7):673–4.CrossRefGoogle Scholar
  47. 47.
    Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450(3):277–89.CrossRefGoogle Scholar
  48. 48.
    • Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314(19):2034–44. The article demonstrated the early use of azithromycin during an apparent lower respiratory tract illnesses reduced the likelihood of severe LRTI in young children with histories of recurrent severe RTI, compared to placebo.CrossRefGoogle Scholar
  49. 49.
    Stokholm J, Chawes BL, Vissing NH, Bjarnadottir E, Pedersen TM, Vinding RK, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(1):19–26.CrossRefGoogle Scholar
  50. 50.
    Yoshihara S, Fukuda H, Tamura M, Arisaka O, Ikeda M, Fukuda N, et al. Efficacy and safety of salmeterol/fluticasone combination therapy in infants and preschool children with asthma insufficiently controlled by inhaled corticosteroids. Drug Res (Stuttg). 2016;66(7):371–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Maleewan Kitcharoensakkul
    • 1
    Email author
  • Leonard B. Bacharier
    • 1
  1. 1.Division of Allergy, Immunology and Pulmonary Medicine, Department of PediatricsWashington University School of MedicineSt. LouisUSA

Personalised recommendations